Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

RBC Capital analyst Luca Issi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $95.00. The ...

Partnership leverages Korro’s proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; ...

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines for ...

Its latest deal is with Cambridge-based Korro Bio Inc. and worth up to $530 million. Korro is developing RNA-editing medicines. The company came into 2024 with 101 full-time employees and is ...

On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most ...

Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for ...

Novo Nordisk and Korro Bio just signed a big collaboration deal. The pair aim to develop medicines involving mRNA, which is Moderna's specialty. Cardiometabolic indications like type 2 diabetes ...